Literature DB >> 9597157

The role of receptor kinases and arrestins in G protein-coupled receptor regulation.

J G Krupnick1, J L Benovic.   

Abstract

G protein-coupled receptors (GPRs) play a key role in controlling hormonal regulation of numerous second-messenger pathways. However, following agonist activation, most GPRs rapidly lose their ability to respond to hormone. For many GPRs, this process, commonly referred to as desensitization, appears to be primarily mediated by two protein families: G protein-coupled receptor kinases (GRKs) and arrestins. GRKs specifically bind to the agonist-occupied receptor, thereby promoting receptor phosphorylation, which in turn leads to arrestin binding. Arrestin binding precludes receptor/G protein interaction leading to functional desensitization. Many GPRs are then removed from the plasma membrane via clathrin-mediated endocytosis. Recent studies have implicated endocytosis in the resensitization of GPRs and have linked both GRKs and arrestins to this process. In this review, we discuss the role of GRKs and arrestins in regulating agonist-specific signaling and trafficking of GPRs.

Mesh:

Substances:

Year:  1998        PMID: 9597157     DOI: 10.1146/annurev.pharmtox.38.1.289

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  238 in total

Review 1.  Regulation of neuronal function by protein trafficking: a role for the endosomal pathway.

Authors:  K M Buckley; H E Melikian; C J Provoda; M T Waring
Journal:  J Physiol       Date:  2000-05-15       Impact factor: 5.182

Review 2.  G-protein coupled receptor kinases as modulators of G-protein signalling.

Authors:  M Bünemann; M M Hosey
Journal:  J Physiol       Date:  1999-05-15       Impact factor: 5.182

3.  The enigma of morphine tolerance: recent insights.

Authors:  S B Ray; S Wadhwa
Journal:  J Biosci       Date:  2001-12       Impact factor: 1.826

4.  Hierarchical phosphorylation of delta-opioid receptor regulates agonist-induced receptor desensitization and internalization.

Authors:  O M Kouhen; G Wang; J Solberg; L J Erickson; P Y Law; H H Loh
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

5.  Desensitization, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference.

Authors:  Seungkirl Ahn; Christopher D Nelson; Tiffany Runyan Garrison; William E Miller; Robert J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-11       Impact factor: 11.205

6.  G protein-independent inhibition of GIRK current by adenosine in rat atrial myocytes overexpressing A1 receptors after adenovirus-mediated gene transfer.

Authors:  Leif I Bösche; Marie-Cécile Wellner-Kienitz; Kirsten Bender; Lutz Pott
Journal:  J Physiol       Date:  2003-06-18       Impact factor: 5.182

7.  beta-Arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha.

Authors:  D Scott Witherow; Tiffany Runyan Garrison; William E Miller; Robert J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-01       Impact factor: 11.205

8.  DARPP-32 and NCS-1 expression is not altered in brains of rats treated with typical or atypical antipsychotics.

Authors:  Bruno R Souza; Bernardo S Motta; Daniela V F Rosa; Karen C L Torres; Adalberto A Castro; Clarissa M Comim; André M Sampaio; Fabrício F Lima; Andreas Jeromin; João Quevedo; Marco A Romano-Silva
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

9.  Effects of the Ras homolog Rhes on Akt/protein kinase B and glycogen synthase kinase 3 phosphorylation in striatum.

Authors:  L M Harrison; S H Muller; D Spano
Journal:  Neuroscience       Date:  2013-02-01       Impact factor: 3.590

Review 10.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.